Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Index fund fees include management fees and other expenses. This brief breaks down what to expect and how fees impact long-term results.
14,622 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Epic Games cuts 1,000 jobs as Fortnite engagement wanes in a challenging market. The move highlights how live-service...
In a year marked by rapid AI expansion, memory plays have emerged as a quiet engine behind stock gains. This hidden s...
Raymond James raises Marathon's target to 270, driven by sustained refining margins and strong MPLX distributions. MP...
Micron Technology stunned investors with a massive quarterly upside. This article breaks down why micron technology's...
Microsoft is staring down a tough start to the year. Is the slide a red flag or a rare chance to buy a tech titan wit...
The Trump administration is weighing a measure to compensate TSA officers who have gone unpaid during a prolonged par...
Rising housing costs and high rates push families to choose between gifting a large down payment now or waiting for a...
Meta has slashed about 25,000 jobs since 2022, with 700 more in Reality Labs this week. The moves spotlight a leaders...
Geopolitics can shake travel stocks fast. This article breaks down how Carnival, the world’s largest cruise operator,...
As overseas conflict persists, American households face higher bills and tighter budgets. This report tracks where co...
A new Grok AI forecast signals a measured gain for Bitcoin, Ethereum, and XRP through May 2026, with upside contingen...